Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事2021年度述职报告（陈命家）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2021. It covers the director's attendance at board and shareholder meetings, independent opinions on various company matters including appointments, related party transactions, audit firm reappointment, internal control evaluations, and protection of investor rights. The content is a comprehensive explanation of the director's duties and activities over the fiscal year, consistent with a management or governance report rather than a simple announcement or certification. It is not an annual report, audit report, or earnings release, but rather a detailed management-related report focusing on the independent director's role and oversight. Therefore, the best fitting category is Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2022-03-30 Chinese
监事会关于2021年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's opinion on the company's 2021 internal control self-evaluation report. It references regulatory requirements and confirms the adequacy and effectiveness of internal controls. The document is short (472 characters) and does not contain detailed financial data or the full internal control report itself, but rather an opinion or verification statement. This fits best under Audit Report / Information (AR), which includes audit reports and internal control evaluations, rather than a full Annual Report or Interim Report. It is not a report publication announcement or a regulatory filing since it contains substantive supervisory opinion content. FY 2021
2022-03-30 Chinese
《公司章程》修订案
Governance Information Classification · 95% confidence The document is titled as a revision proposal to the company's Articles of Association (公司章程修订案) dated March 2022. It details specific amendments to the company's bylaws, including governance structure, shareholder meeting procedures, board responsibilities, and compliance with regulatory guidelines such as those from the China Securities Regulatory Commission (CSRC). The content is focused on governance rules and internal company regulations rather than financial results, audit opinions, or shareholder meeting results. It is not a report of financial performance or an announcement of voting results. The document is a governance-related update to the company's internal rules and bylaws, fitting the Governance Information (CGR) category.
2022-03-30 Chinese
2021年度内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls related to financial reporting for the fiscal year ending December 31, 2021. The document includes the auditor's responsibilities, the company's responsibilities, and an assurance conclusion on the internal control effectiveness. It is a standalone audit-related report focusing on internal control over financial reporting, not a full annual report or financial statement. The document length is short (1448 characters), but it contains substantive content of an audit assurance report rather than just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2021
2022-03-30 Chinese
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Deposit and Use of Raised Funds." It is issued by an accounting firm and addresses the shareholders, providing an independent verification conclusion on the company's 2021 annual report regarding the use and deposit of raised funds. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to the management and use of raised funds. The content is a standalone audit/verification report focusing on the use of capital raised by the company, not a full annual report or financial statement. The document length is 1342 characters, which is short but contains the full verification report text, not just an announcement. Therefore, it fits the category of an Audit Report / Information (AR) rather than an Annual Report (10-K) or a Report Publication Announcement (RPA). FY 2021
2022-03-30 Chinese
关于使用闲置自有资金和闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the use of idle self-owned funds and idle raised funds for cash management. It details the board and supervisory approvals, independent directors' opinions, and the scope and risk control measures of the cash management plan. The document references regulatory approvals and compliance with securities regulations but does not contain financial statements or detailed financial results. It is a formal disclosure about financing activities related to the company's capital management rather than a full financial report or earnings release. The document length is 3643 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-30 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.